HLH: Every specialty's business - the updated GIRFT guidance and lessons from clinical practice

HLH: Every specialty's business - the updated GIRFT guidance and lessons from clinical practice

HLH is every specialty’s business. Recognising HLH early and delivering effective multidisciplinary care can make a critical difference to patient outcomes. This webinar explores how services can improve diagnosis, treatment and management of the potentially devastating condition.

Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterised by uncontrolled immune activation, hyperinflammation and progressive tissue damage, which can lead to multi-organ failure. With a crude mortality rate of around 50%, timely recognition and coordinated treatment of HLH is essential.

GIRFT has updated its HLH pathway and supporting guidance. This webinar will explore what has changed and why the updated guidance matters.

Dr Peter Lanyon, GIRFT Joint Clinical Lead for Rheumatology, and the chairs of the UK HLH National Advisory Panel, Dr Rachel Tattersall (Sheffield Teaching Hospitals and Sheffield Children's Hospital) and Dr Jessica Manson (University College London Hospitals), will introduce the updated pathway and discuss its key recommendations.

The lead authors will then be joined by consultants in infectious diseases, microbiology, haematology and paediatric rheumatology to share practical lessons from clinical experience, including how multidisciplinary approaches have been implemented and the difference they have made to service delivery in their trusts.

Register here to learn about the updated guidance and its implications for the diagnosis and management of HLH.

The joining link will be sent by separate email nearer the event date. 

Questions about this event?

Questions about this event?

Name: sophie sheard

Email: sophie.sheard1@nhs.net

Telephone: 07876 478799